

Claim 2. (Amended) [A] The composition of Claim 1 wherein said bioactive substance is present in about 1 to 10% w/v.

Claim 3. (Amended) [A] The composition of Claim 1 wherein said poly(lactide-co-glycolide) copolymer is present in about 1 to 10% w/v.

A 1
Claim 4. (Amended) [A] The composition of Claim 1 wherein the ratio of said hydrophilic and lipophilic solvents is from about 65:35 to about 35:65.

Claim 5. (Amended) [A] The composition of Claim 1 which comprises:
(a) 1 to 10% w/v of a hydrophobic bioactive substance;
(b) 1 to 10% w/v of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the hydrophobic bioactive substance is 1:1 or less; and
(c) a mixture of hydrophilic and lipophilic solvents is from about 65:35 to about 35:65.

Claim 6. (Amended) [A] The composition of Claim 1 which comprises:
(a) 5 to 10% w/v of a hydrophobic bioactive substance;
(b) 5 to 10% w/v of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the hydrophobic bioactive substance is 1:1 or less; and
(c) a mixture of hydrophilic and lipophilic solvents is from about 65:35 to about 35:65.

Claim 7. (Amended) [A] The composition of Claim 1 wherein said bioactive substance is selected from fipronil, the avermectins, ivermectins, eprinomectin, milbemycins, nodulisporic acid and derivatives thereof, estradiol benzoate, trenbolone acetate, progesterone, and norethisterone.

Claim 8. (Amended) [A] The composition of Claim 1 wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 95:5 to about 50:50.

B1
Claim 9. (Amended) [A] The composition of Claim 1 wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35.

A1
Claim 10. (Amended) [A] The composition of Claim 1 wherein said hydrophilic solvent is selected from glycerol formal, glycofural, N-methyl pyrrolidone, 2-pyrrolidone, isopropylidene glycerol, di(propylene glycol) methyl ether, and mixtures thereof.

Cond
Claim 11. (Amended) [A] The composition of Claim 1 which comprises:
(a) 5 to 10% w/v of a hydrophobic bioactive substance;
(b) 5 to 10% w/v of a poly(lactide-co-glycolide) copolymer; wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35, and the weight ratio of the poly(lactide-co-glycolide) copolymer to the hydrophobic bioactive substance is 1:1 or less; and
(c) a mixture of glycerol formal and triacetin wherein the volume ratio of glycerol formal and triacetin is from about 65:35 to about 35:65.

Sub B1
AZ
Claim 13. (Amended) A liquid polymeric composition comprising:
(a) about 1-30% w/v of at least one bioactive substance;
(b) about 1-20% w/v of at least one biologically acceptable polymer, wherein the weight ratio of the polymer to the bioactive substance is 1:1 or less; and
(c) at least one lipophilic solvent or a mixture of at least one hydrophilic solvent and at least one lipophilic solvent, wherein the volume ratio of the hydrophilic and lipophilic solvents is from about 80:20 to about 0:100, and/or wherein the lipophilic solvent is present in an amount of at least about 16.5% by weight;
wherein said composition is effective to form a film encapsulated liquid in situ.

Remarks

The claims are 1-14. Claims 1-3, 5, 6, 11, and 13 have been amended to recite the percentage ranges of the hydrophobic bioactive substance, the poly(lactide-co-glycolide) copolymer, and the biologically acceptable polymer is being w/v as stated in the original